|
Volumn 1, Issue 9, 2016, Pages 971-972
|
Angiotensin neprilysin inhibition for patients with heart failure: What if sacubitril/valsartan were a treatment for cancer?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANGIOTENSIN RECEPTOR ANTAGONIST;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ENALAPRIL;
SACUBITRIL PLUS VALSARTAN;
ALZHEIMER DISEASE;
CARDIOVASCULAR MORTALITY;
DRUG COST;
DRUG DOSE TITRATION;
DRUG SAFETY;
DRUG SUBSTITUTION;
DRUG WITHDRAWAL;
HEART FAILURE;
HEART FAILURE WITH REDUCED EJECTION FRACTION;
HOSPITALIZATION;
HUMAN;
HYPERKALEMIA;
HYPOTENSION;
KIDNEY FAILURE;
PRIORITY JOURNAL;
REMISSION;
SHORT SURVEY;
SUDDEN DEATH;
|
EID: 85026544074
PISSN: 23806583
EISSN: 23806591
Source Type: Journal
DOI: 10.1001/jamacardio.2016.3053 Document Type: Short Survey |
Times cited : (19)
|
References (7)
|